Effects of rIL2/anti-IL2 antibody complex on chikungunya virus-induced chronic arthritis in a mouse model

Authors

Sarah R. Tritsch, Milken Institute School of Public Health, The George Washington University, Washington, D.C., USA. sarahtritsch@gwu.edu.
Abigail J. Porzucek, Milken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Arnold M. Schwartz, School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Abigale M. Proctor, Milken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Richard L. Amdur, School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Patricia S. Latham, School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Gary L. Simon, School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Christopher N. Mores, Milken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Aileen Y. Chang, School of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA. chang@gwu.edu.

Document Type

Journal Article

Publication Date

5-5-2023

Journal

Scientific reports

Volume

13

Issue

1

DOI

10.1038/s41598-023-34578-x

Abstract

Chikungunya virus (CHIKV) is characterized by disabling joint pain that can cause persistent arthritis in approximately one-fourth of patients. Currently, no standard treatments are available for chronic CHIKV arthritis. Our preliminary data suggest that decreases in interleukin-2 (IL2) levels and regulatory T cell (Treg) function may play a role in CHIKV arthritis pathogenesis. Low-dose IL2-based therapies for autoimmune diseases have been shown to up-regulate Tregs, and complexing IL2 with anti-IL2 antibodies can prolong the half-life of IL2. A mouse model for post-CHIKV arthritis was used to test the effects of recombinant IL2 (rIL2), an anti-IL2 monoclonal antibody (mAb), and the complex on tarsal joint inflammation, peripheral IL2 levels, Tregs, CD4 + effector T cells (Teff), and histological disease scoring. The complex treatment resulted in the highest levels of IL2 and Tregs, but also increased Teffs, and therefore did not significantly reduce inflammation or disease scores. However, the antibody group, which had moderately increased levels of IL2 and activated Tregs, resulted in a decreased average disease score. These results suggest the rIL2/anti-IL2 complex stimulates both Tregs and Teffs in post-CHIKV arthritis, while the anti-IL2 mAb increases IL2 availability enough to shift the immune environment towards a tolerogenic one.

APA Citation

Tritsch, Sarah R.; Porzucek, Abigail J.; Schwartz, Arnold M.; Proctor, Abigale M.; Amdur, Richard L.; Latham, Patricia S.; Simon, Gary L.; Mores, Christopher N.; and Chang, Aileen Y., "Effects of rIL2/anti-IL2 antibody complex on chikungunya virus-induced chronic arthritis in a mouse model" (2023). GW Authored Works. Paper 2941.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2941

Department

Medicine